D. Yamada

发表

Prevalence of resistant hypertension and associated factors in Japanese subjects with type 2 diabetes.

H. Yokoyama, H. Sone, S. Araki, 2015, Diabetes Research and Clinical Practice.

Risks for glomerular filtration rate decline in association with progression of albuminuria in type 2 diabetes.

H. Yokoyama, H. Sone, M. Haneda, 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Determinants of decline in glomerular filtration rate in nonproteinuric subjects with or without diabetes and hypertension.

H. Yokoyama, H. Sone, H. Itoh, 2009, Clinical journal of the American Society of Nephrology : CJASN.

Risk factors associated with abnormal cognition in Japanese outpatients with diabetes, hypertension or dyslipidemia

H. Yokoyama, H. Sone, M. Haneda, 2015, Diabetology International.

Between Remission of Macroalbuminuria and Preservation of Renal Function i n Patients With Typ e 2 Diabetes Mellitus With Overt Proteinuria

H. Yokoyama, H. Sone, S. Araki, 2013 .

Association Between Remission of Macroalbuminuria and Preservation of Renal Function in Patients With Type 2 Diabetes With Overt Proteinuria

H. Yokoyama, H. Sone, S. Araki, 2013, Diabetes Care.

A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.

Y. Yamasaki, P. Kolkhof, S. Katayama, 2017, Journal of diabetes and its complications.

Contribution of glimepiride to basal-prandial insulin therapy in patients with type 2 diabetes.

H. Yokoyama, H. Sone, M. Haneda, 2011, Diabetes research and clinical practice.

Acute Effects of Insulin on Fibrinolytic System in Patients with Essential Hypertension

K. Mizuno, S. Midorikawa, D. Yamada, 1997 .

Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus.

S. Midorikawa, W. Sato, D. Yamada, 2000, Metabolism: clinical and experimental.

The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients.

D. Yamada, S. Neugebauer, T. Baba, 2001, Diabetes care.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Debra F. Weinstein, Michael G. Miller, M. A. Ferreira, 2019, Lancet.

A nondiabetic case of hemoglobin variant (Hb Niigata) with inappropriately high and low HbA1c titers detected by different methods.

S. Midorikawa, M. Miura, W. Sato, 1998, Clinical chemistry.

Direct evidence for erythropoietin-induced release of endothelin from peripheral vascular tissue.

K. Mizuno, D. Yamada, S. Fukuchi, 1994, Life sciences.

Improvement by Thiazolidinediones of Vascular Endothelial Cell Dysfunction in Diabetic Patients: A Possible New Physiological Role of PPARγ

H. Satoh, S. Midorikawa, Tsuyoshi Watanabe, 2000 .

Plasma vascular endothelial growth factor in Japanese Type 2 diabetic patients with and without nephropathy.

S. Midorikawa, W. Sato, D. Yamada, 2002, Journal of diabetes and its complications.

Postprandial hypoglycaemia due to insulin lispro

K. Tanaka, E. Hosoya, M. Fujiwara, 2004, Diabetic medicine : a journal of the British Diabetic Association.

Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.

T. Watanabe, T. Fujita, Y. Endo, 1999, Biochemical and biophysical research communications.

Relationship between a low ankle brachial index and all-cause death and cardiovascular events in subjects with and without diabetes.

Masakazu Haneda, Hirohito Sone, H. Yokoyama, 2014, Journal of atherosclerosis and thrombosis.

Mmol/l at 95% Confidence from Commonly Estimated a Nondiabetic Case of Hemoglobin Variant (hb Ni- Igata) with Inappropriately High and Low Hba1c Titers Detected by Different Methods, Tsuyoshi Watanabe, 1*

S. Midorikawa, Tsuyoshi Watanabe, M. Miura, 1998 .

Flow-mediated dilation is associated with microalbuminuria independent of cardiovascular risk factors in type 2 diabetes - interrelations with arterial thickness and stiffness.

H. Yokoyama, H. Sone, M. Haneda, 2011, Journal of atherosclerosis and thrombosis.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Debra F. Weinstein, Michael G. Miller, M. A. Ferreira, 2019, Lancet.

Aflibercept (VEGF TRAP) in advanced ovarian cancer patients with recurrent symptomatic malignant ascites: results of a randomized, double-blind, placebo-controlled study

D. Provencher, H. Hirte, I. Vergote, 2009 .